Related Experiment Video
Updated: Jun 18, 2026
11:17
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Resection in stage I/II non-small cell lung cancer
Frontiers of Radiation Therapy and Oncology
|December 4, 2009
Summary
Surgery, particularly lobectomy, is the primary treatment for early-stage non-small cell lung cancer (NSCLC), offering high survival rates. Minimally invasive approaches show promise but are not yet routine for NSCLC.
Area of Science:
- Thoracic Surgery
- Surgical Oncology
- Pulmonology
Background:
- Surgery is the main curative treatment for early-stage non-small cell lung cancer (NSCLC).
- Lobectomy offers the best cure rates for stage Ia/Ib NSCLC, with survival between 58-76%.
Purpose of the Study:
- To review the surgical treatment options for early-stage non-small cell lung cancer (NSCLC).
- To discuss the efficacy and limitations of different surgical approaches for NSCLC based on tumor stage.
Main Methods:
- Review of current surgical practices for non-small cell lung cancer (NSCLC).
- Analysis of survival rates and prognostic factors associated with different surgical interventions.
Main Results:
- Video-thoracoscopic lobectomy provides results comparable to open surgery for stage Ia NSCLC.
- Minimally invasive lobar resections are not routine due to specimen harvesting and lymph node dissection challenges.
- Minor resections are effective for small tumors (<2 cm) but have lower curative potential.
- Stage II NSCLC requires lobectomy or pneumonectomy, with sleeve resection an option for central tumors.
Conclusions:
- Lobectomy remains the gold standard for early-stage NSCLC (Ia/Ib).
- Surgical approach (open vs. minimally invasive) has comparable outcomes for stage Ia.
- Advanced stages (II) necessitate more extensive surgery like pneumonectomy for oncological control.
